MedTrace Logo

A Study of TCR-Redirected T Cell Infusion in Subject With Recurrent HBV-related HCC Post Liver Transplantation

NCT02719782 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2018-11-16

No results posted yet for this study

Summary

Hepatocellular carcinoma (HCC) recurrence rate is high among liver transplant patients, while treatment measures are limited. This study plans to recruit 10 patients with Hepatitis B virus (HBV) related HCC who underwent liver transplantation and are confirmed to have recurrent HCC. The objective of the study is to assess the safety, tolerability and effectiveness of the HBV specific T cell receptor (HBV/TCR) redirected T cell in the target population.

Conditions

  • Recurrent Hepatocellular Carcinoma

Interventions

BIOLOGICAL

Biological: TCR-T

Autologous T cells transfected with mRNA encoding HBV antigen-specific TCR

Sponsors & Collaborators

  • Agency for Science, Technology and Research

    collaborator OTHER

  • Third Affiliated Hospital, Sun Yat-Sen University

    collaborator OTHER

  • Lion TCR Pte. Ltd.

    lead INDUSTRY

Principal Investigators

  • Qi Zhang, MD · Third Affiliated Hospital, Sun Yat-Sen University

  • Antonio Bertoletti, MD · Duke-NUS Graduate Medical School

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-07-02
Primary Completion
2019-05-31
Completion
2019-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02719782 on ClinicalTrials.gov